Particle-based vaccines for transcutaneous vaccination

Comp Immunol Microbiol Infect Dis. 2008 Mar;31(2-3):293-315. doi: 10.1016/j.cimid.2007.07.015. Epub 2007 Oct 30.

Abstract

Immunization concepts evolve with increasing knowledge of how the immune system works and the development of new vaccination methods. Traditional vaccines are made of live, attenuated, killed or fragmented pathogens. New vaccine strategies can take advantage of particulate compounds--microspheres or nanoparticles--to target antigen-presenting cells better, which must subsequently reach the secondary lymphoid organs, which are the sites of the immune response. The use of the skin as a target organ for vaccine delivery stems from the fact that immature dendritic cells (DCs), which are professional antigen-presenting cells can be found at high density in the epidermis and dermis of human or animal skin. This has led to design various methods of dermal or transcutaneous vaccination. The quality and duration of the humoral and cellular responses to vaccination depend on the appropriate targeting of antigen-presenting cells, of the vaccine dose, route of administration and use of adjuvant. In this review, we will focus on the use of micro- and nano-particles to target the skin antigen-presenting cells and will discuss recent advances in the field of transcutaneous vaccination in animal models and humans.

Publication types

  • Review

MeSH terms

  • Administration, Cutaneous
  • Animals
  • Humans
  • Nanoparticles*
  • Skin / immunology
  • Vaccines / administration & dosage*
  • Vaccines / immunology

Substances

  • Vaccines